Novartis leadership reshuffle brings Biogen Idec talent to Sandoz
This article was originally published in Scrip
Executive Summary
Jeff George, head of Novartis's generics business Sandoz since December 2008, is to take over the leadership of its eye care business Alcon. He will replace the retiring Kevin Buehler, who has been with the company for 30 years. Mr George's replacement at Sandoz is Biogen Idec's senior vice president, US commercial operations, Richard Francis.
You may also be interested in...
Top 10 Best-Selling Drugs Of Q2 2023: COVID-19 Out, HPV In
The Merck & Co vaccine for human papillomavirus Gardasil, along with Johnson & Johnson’s Darzalex for multiple myeloma, entered the ranks of the top 10 best-selling drugs globally in the second quarter. There was no product for COVID-19 in the line-up for the first time since 2020.
Titans Of Pharma: Pfizer’s Bourla Tops Big Pharma CEO Compensation League
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.
Titans Of Pharma: Pfizer’s Bourla Tops Big Pharma CEO Compensation League
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.